» Articles » PMID: 25975578

The RET Fusion Gene and Its Correlation with Demographic and Clinicopathological Features of Non-small Cell Lung Cancer: a Meta-analysis

Overview
Specialties Oncology
Pharmacology
Date 2015 May 16
PMID 25975578
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The RET fusion gene is a novel oncogene observed in a subset of NSCLC in recent years. Nevertheless, the results of epidemiological studies concerning the gene remain unclear. Thus, a meta-analysis was conducted to evaluate the correlation of RET fusion gene with demographic and clinicopathological features of NSCLC.

Methods: PubMed, Embase, and Web of Science databases were searched to identify eligible studies. The association of RET fusion gene occurrence with gender, age, smoking status, histology type and tumor stage were analyzed in meta-analysis. Subgroup analysis according to patients' location (Asian and non-Asian) was also conducted. Odds ratio (OR) and 95% confidence interval (95% CI) were calculated to assess the correlation.

Results: Nine studies with a total of 6,899 NSCLC patients met the inclusion criteria. A total of 84 patients with RET fusion gene were detected. The RET fusion gene was identified at significantly higher frequencies in female (OR = 0.55, 95%CI = 0.35-0.85) than male patients and in young (<60) patients (OR = 0.43, 95%CI = 0.19-0.99) than old patients (≤60), particularly in patients from Asian. A significant higher frequency was also identified in non-smokers (OR = 0.28, 95% CI = 0.16-0.49), and in patients with lung adenocarcinomas (OR = 3.59, 95%CI = 1.50-8.56). Additionally, no association between RET fusion gene and the TNM stage of tumor was observed.

Conclusion: RET fusion gene occurred predominantly in Asian females with younger age, in non-smokers, and in lung adenocarcinomas patients. This subset of NSCLC patients might be good candidates for personalized diagnostic and therapeutic approaches.

Citing Articles

First-line selpercatinib for a patient with fusion-positive pulmonary large cell neuroendocrine carcinoma.

Eihuku T, Miwa S, Oshima T, Ohba H, Shirai M Respir Med Case Rep. 2024; 52:102116.

PMID: 39350958 PMC: 11440289. DOI: 10.1016/j.rmcr.2024.102116.


Combining demographic data and transvaginal ultrasonography: a predictive model for endometrial carcinoma in postmenopausal patients.

Li X, Wang H, Wang T, Cui H, Wu L, Wang W BMC Womens Health. 2024; 24(1):539.

PMID: 39334255 PMC: 11429476. DOI: 10.1186/s12905-024-03374-8.


Diagnosis, Treatment Patterns, and Outcomes in Real-World Patients with RET Fusion-Positive Non-small Cell Lung Cancer in China.

Lu S, Shen L, Wang Q, Chen H, Zhao Y, Li Y Adv Ther. 2024; 41(11):4248-4265.

PMID: 39316291 DOI: 10.1007/s12325-024-02983-x.


Molecular Landscape and Therapeutic Strategies against Colorectal Cancer.

Patel A, Gulhati P Cancers (Basel). 2024; 16(8).

PMID: 38672633 PMC: 11049251. DOI: 10.3390/cancers16081551.


Lung cancer in patients who have never smoked - an emerging disease.

Lopiccolo J, Gusev A, Christiani D, Janne P Nat Rev Clin Oncol. 2024; 21(2):121-146.

PMID: 38195910 PMC: 11014425. DOI: 10.1038/s41571-023-00844-0.


References
1.
Girard N . Other signalization targets. Target Oncol. 2013; 8(1):69-77. DOI: 10.1007/s11523-012-0246-5. View

2.
Tsuta K, Kohno T, Yoshida A, Shimada Y, Asamura H, Furuta K . RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Br J Cancer. 2014; 110(6):1571-8. PMC: 3960615. DOI: 10.1038/bjc.2014.36. View

3.
Takahashi M, Ritz J, Cooper G . Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985; 42(2):581-8. DOI: 10.1016/0092-8674(85)90115-1. View

4.
Cote M, Kardia S, Wenzlaff A, Ruckdeschel J, Schwartz A . Risk of lung cancer among white and black relatives of individuals with early-onset lung cancer. JAMA. 2005; 293(24):3036-42. DOI: 10.1001/jama.293.24.3036. View

5.
Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H . ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer. 2014; 84(2):121-6. DOI: 10.1016/j.lungcan.2014.02.007. View